News End of the line for Cassava's troubled Alzheimer's programme The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.
News End looms for Cassava's simufilam in Alzheimer's disease Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end
R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
News SEC charges Cassava over 'misleading' Alzheimer's claims The US financial regulator has accepted a $40 million-plus settlement from Cassava Sciences and two of its former executives for making what it alleges are misleading statements about the r
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.